AEON
What one share of AEON Biopharma holds
Pharmaceutical Preparations
AEON is a biopharmaceutical company advancing its proprietary botulinum toxin complex ABP-450 as a biosimilar to Botox® (onabotulinumtoxinA) with the goal of achieving full-label United States (“U.S.”) market entry for debilitating medical conditions.
AEON Biopharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.90 |
|---|---|
| Cash and investments | $0.13 |
| Debt | $0.07 |
| Book value | −$0.58 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | $72.93 | — | −$35.23 | — | −$51.43 |
| 2025 | — | −$3.95 | $0.00 | −$1.74 | — | −$4.55 |